Hypoxia-inducible factor-2α mRNA expression in human renal cell carcinoma

References

• Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38–47
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721–32
   PubMed Web of Science ®Google Scholar
• Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291: F271–81
   PubMedGoogle Scholar
• Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix- loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510–4
   PubMed Web of Science ®Google Scholar
• Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004; 36: 530–9
   PubMed Web of Science ®Google Scholar
• Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1: 247–55
   PubMed Web of Science ®Google Scholar
• Kondo K, Klco J, Nakamura E., Lechpammer M, Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1: 237–46
   PubMed Web of Science ®Google Scholar
• Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, et al. Expression of hypoxia-inducible factors in human renal cell cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62: 2957–61
   PubMed Web of Science ®Google Scholar
• Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005; 11: 1129–35
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006; 24: 727–35
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991–5004
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–5
   PubMed Web of Science ®Google Scholar
• Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 5435–43
   PubMed Web of Science ®Google Scholar
• Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology 2005; 65: 1090–5
   PubMedGoogle Scholar
• Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94: 1569–75
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131–3
   PubMed Web of Science ®Google Scholar
• Sobin, L, Wittekind, CH, International Union Against Cancer (UICC) TNM Classification of malignant tumours. 6th ed. 2002. p 193–195.
   Google Scholar
• Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655–63
   PubMed Web of Science ®Google Scholar
• Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996; 274: 2057–9
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Marincola FM. Quantitative real-time PCR in cancer research. Arch Immunol Ther Exp (Warsz) 2003; 51: 301–13
   PubMedGoogle Scholar
• Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1: E83
   PubMed Web of Science ®Google Scholar
• Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003; 63: 6130–4
   PubMed Web of Science ®Google Scholar
• Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau- associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675–86
   PubMed Web of Science ®Google Scholar
• Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF- 2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264–70
   PubMed Web of Science ®Google Scholar
• Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 2006; 97: 706–10
   PubMed Web of Science ®Google Scholar
• Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol 2007; 28: 158–64
   PubMed Web of Science ®Google Scholar
• Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007; 100: 556–60
   PubMed Web of Science ®Google Scholar
• Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, et al. The real-time polymerase chain reaction. Mol Aspects Med 2006; 27: 95–125
   PubMedGoogle Scholar